Because research peptides are sold without pharmaceutical oversight, a third-party Certificate of Analysis (CoA) — verifying identity and purity — is the single most important trust signal a buyer can check. We monitor 11 well-known vendors (9 currently active) across 10 weighted transparency criteria. Here is what the market actually looks like in 2026.
| Transparency criterion | Vendors meeting it (of 9 active) |
|---|
| Publishes Certificates of Analysis | 7 / 9 |
| CoAs accessible before purchase (no account) | 7 / 9 |
| Names an independent third-party lab | 6 / 9 |
| Provides batch/lot-level CoAs | 6 / 9 |
| CoA verifiable at the lab's own source | 2 / 9 |
| Publishes sterility / endotoxin data | 2 / 9 |
💬 Quotable: "In 2026, 7 of 9 active research-peptide vendors publish a Certificate of Analysis — but only 2 of 9 publish CoAs that can be verified directly at the testing lab, and only 2 of 9 disclose sterility or endotoxin results."
Across the active vendors we track, the average transparency score is 73 / 100, ranging from a high of 92.5 down into the 40s. The gap between "publishes a document" and "publishes a document you can independently verify" is the defining transparency problem of the sector.